Bellus Labs, a New Jersey-based private label and custom formulation laboratory, is celebrating a decade of sustained growth. Founded in 2015 by chemist and CEO Kristina Cimo and her husband, Michael, ...

After GSK’s $2 billion buyout of Canada-based Bellus Health last summer, an undisclosed number of the biotech’s team members are out of a job. “When two companies come together during an acquisition, ...

The purchase will include a promising drug candidate for treating chronic cough. If approved, camlipixant could see peak sales of $1.2 billion in the U.S. alone. With the acquisition anticipated to ...

GSK is set to acquire Bellus Health for $14.75 per share of common stock in cash representing an approximate total equity value of $2 billion. Bellus is a Canada-based, late-stage biopharmaceutical ...

Bellus' lead therapy, camlipixant, is being tested against refractory chronic cough. The company is a clinical-stage biotech with no marketed therapies. Bellus finished 2022 with $337.1 million. The ...

April 18 (Reuters) - GSK (GSK.L), opens new tab plans to buy Canada-based drug developer Bellus Health Inc (BLU.TO), opens new tab in an all-cash deal for $2 billion as the British drugmaker expands ...

Recurrent chronic cough has no FDA-approved treatments, but efforts are underway to bring one to the market. GSK sees a late-stage drug candidate from Bellus Health as potentially best in class and ...

Pharma giant GlaxoSmithKline on Tuesday announced a deal to buy Canadian biotech Bellus Health for $2 billion, betting big on the firm’s cough medicine as it moves to shore up its slender drug ...

GSK Plc agreed to buy Canadian biotech Bellus Health Inc. for about $2 billion to bolster its pipeline of experimental medicines. The UK drugmaker will pay $14.75 per share in cash for Bellus, a 103% ...

(Reuters) -GSK plans to buy Canada-based drug developer Bellus Health Inc in an all-cash deal for $2 billion as the British drugmaker expands its bet on respiratory therapies. The move to replenish ...

GSK (NYSE:GSK) is acquiring Canadian biotech Bellus Health (NASDAQ:BLU) for ~$2B (~£1.6B) in cash. The British pharma giant will acquire outstanding shares of Bellus for US$14.75 per share in cash.